CorePharma's Generic Dicyclomine Hydrochloride Receives Approval in the U.S.
The story of Martin Shkreli and the drug, Daraprim, has been used as an example of drug company greed. Daraprim is used to treat a parasitic disease known as toxoplasmosis, which can be life-threatening in people with compromised immune systems. In 2015, Turing Pharmaceuticals, where Shkreli was CEO, acquired the rights to Daraprim from CorePharma, and promptly raised the price from $12.50 a tablet to $750. The rationale for such an outrageous price hike was that this was a life-saving drug and should be priced accordingly. However, Daraprim is a generic drug, one that has been the market for 70 years! There are numerous other life-saving drugs that are generic and have also been on the market for decades. Yet, these drugs are very modestly priced. Shkreli was vilified for this. Fortunately, Shkreli’s behaviors have not been mimicked – until now.
CorePharma's Generic Chlorzoxazone Receives Approval in the U.S.
CorePharma's Generic Chlordiazepoxide HCL;Clidinium bromide Receives Approval in the U.S.
CorePharma's Generic Clorazepate Dipotassium Receives Approval in the U.S.
CorePharma to reopen under new ownership following Impax sale
A group of industry investors has announced the acquisition of CorePharma, LLC, its facilities and equipment in Middlesex, NJ from Impax Laboratories, Inc (NASDAQ: IPXL). Henceforth, this ownership group will have 100% equity interest in CorePharma, LLC.
Corepharma`s Generic Glyburide approved in US for Type 2 diabetes
Corepharma`s Generic Metaxalone (400Mg) Approved In USA For Acute Painful Muscle Conditions